Breaking News

WuXi PharmaTech Completes St. Paul Facility Expansion

May 12, 2014

Expands materials characterization testing services in St. Paul

WuXi PharmaTech, Inc. has completed the expansion of its materials characterization testing facility in St. Paul, MN. The new lab will begin operations by the end of June. 
 
The new 20,000-sq.-ft. lab will offer expanded capacity for existing services, such as particle identification and extractable/leachable testing, and its new service, dynamic light scattering for nanoparticle characterization. The expansion is designed to allow rapid scale-up of technologies to increase capacities for chemical analysis of medical materials.  
 
"WuXi is committed to helping medical device and biologics companies bring their products to market faster," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "This facility and WuXi's trained staff will better serve our customers' growing need to quantify the chemical safety of materials used in medical devices and biologics."
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug